
Pacific Biosciences of California PACB
$ 1.87
8.09%
Quarterly report 2025-Q3
added 11-06-2025
Pacific Biosciences of California General and Administrative Expenses 2011-2026 | PACB
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Pacific Biosciences of California
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 170 M | 161 M | 124 M | 72.8 M | 75.5 M | 63.5 M | 59.1 M | 47.8 M | 45.2 M | 38 M | 38.7 M | 47.7 M | 46.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 170 M | 38 M | 76.1 M |
Quarterly General and Administrative Expenses Pacific Biosciences of California
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.1 M | 36.2 M | - | 43.7 M | 45.9 M | 43.8 M | - | 43.4 M | 40.6 M | 39.8 M | - | 36.8 M | 39.3 M | 39.8 M | - | 31.6 M | 29.1 M | 26.1 M | - | 14.8 M | 15.1 M | 24.9 M | - | 20.1 M | 19.1 M | 19.8 M | - | 13.5 M | 14.9 M | 14.9 M | - | 14 M | 15.5 M | 15.3 M | - | 11.9 M | 11.2 M | 11.7 M | - | 10.8 M | 10.8 M | 10.8 M | - | 9.88 M | 8.99 M | 9.15 M | - | 10.8 M | 9.37 M | 9.55 M | - | 10.1 M | 11.6 M | 15.3 M | - | 12.8 M | 11 M | 11.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 45.9 M | 8.99 M | 21 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
Brainsway Ltd.
BWAY
|
5.78 M | $ 19.02 | 0.21 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
490 M | $ 20.15 | -2.3 % | $ 217 M | ||
|
Co-Diagnostics
CODX
|
14.3 M | $ 0.17 | -6.7 % | $ 4.99 M | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Danaher Corporation
DHR
|
7.76 B | $ 228.92 | -0.76 % | $ 167 B | ||
|
BioNano Genomics
BNGO
|
51.9 M | $ 1.53 | 2.0 % | $ 1.94 M | ||
|
DexCom
DXCM
|
1.19 B | $ 66.37 | -1.03 % | $ 25.6 B | ||
|
Castle Biosciences
CSTL
|
200 M | $ 38.9 | -1.04 % | $ 1.08 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
DarioHealth Corp.
DRIO
|
18.1 M | $ 11.38 | 6.36 % | $ 323 M | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
191 M | $ 101.56 | -0.33 % | $ 18.8 B | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 26.27 | -0.83 % | $ 794 M | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
118 M | $ 18.84 | -1.21 % | $ 1.01 B | ||
|
IQVIA Holdings
IQV
|
1.99 B | $ 225.41 | -1.0 % | $ 40.9 B | ||
|
Celcuity
CELC
|
9.06 M | $ 99.74 | -0.18 % | $ 3.93 B | ||
|
Anixa Biosciences
ANIX
|
7.44 M | $ 3.12 | - | $ 99.5 K | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
Guardant Health
GH
|
180 M | $ 102.14 | 1.53 % | $ 12.5 B | ||
|
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | ||
|
ENDRA Life Sciences
NDRA
|
7.06 M | $ 4.53 | -4.83 % | $ 2.43 M | ||
|
Myriad Genetics
MYGN
|
276 M | $ 6.15 | -0.32 % | $ 557 M | ||
|
NeoGenomics
NEO
|
260 M | $ 11.76 | -3.84 % | $ 1.49 B | ||
|
Illumina
ILMN
|
1.09 B | $ 131.16 | -1.2 % | $ 20.9 B | ||
|
Charles River Laboratories International
CRL
|
751 M | $ 199.48 | -1.24 % | $ 10.2 B | ||
|
National Research Corporation
NRC
|
46.6 M | $ 18.77 | 0.64 % | $ 461 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.77 B | $ 173.53 | -1.12 % | $ 19.3 B | ||
|
Biodesix
BDSX
|
80.5 M | $ 6.8 | 1.19 % | $ 882 M | ||
|
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | ||
|
Laboratory Corporation of America Holdings
LH
|
2.23 B | $ 250.88 | -0.87 % | $ 21 B | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 182.22 | -0.43 % | $ 15 B | ||
|
IDEXX Laboratories
IDXX
|
442 M | $ 676.53 | -0.85 % | $ 55.8 B | ||
|
Lantheus Holdings
LNTH
|
194 M | $ 66.55 | -0.91 % | $ 4.61 B | ||
|
Mettler-Toledo International
MTD
|
936 M | $ 1 394.19 | -1.42 % | $ 29.6 B | ||
|
Agilent Technologies
A
|
1.62 B | $ 136.07 | -1.13 % | $ 41.4 B | ||
|
Precipio
PRPO
|
9.45 M | $ 22.98 | -1.84 % | $ 29.8 M | ||
|
Biomerica
BMRA
|
2.98 M | $ 2.52 | 2.86 % | $ 5.79 M | ||
|
Bioventus
BVS
|
304 M | $ 7.44 | -0.13 % | $ 466 M | ||
|
Personalis
PSNL
|
46.2 M | $ 7.96 | -0.13 % | $ 472 M |